PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34312587-10	2021	whereas Lopinavir (- 7.7 kcal/mol) exhibited the strongest affinity for RdRp.	Lopinavir	8-17	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	72-76	
32729392-4	2021	Molecular docking on 40 derivatives of standard drugs (Remdesivir, Lopinavir and Theophylline) led to the identification of R10, R2 and L9 as potential inhibitors of 3CLpro, PLpro and Spike protein, respectively.	Lopinavir	67-76	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	174-179	
33251975-4	2022	Small molecules such as lopinavir and favipiravir significantly inhibit the activity of Mpro and RdRp in vitro.	Lopinavir	24-33	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	97-101	
33251975-5	2022	Studies have shown that structurally modified lopinavir, favipiravir, and other similar compounds can inhibit COVID-19 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp).	Lopinavir	46-55	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	174-178	
33251975-9	2022	Molecular interaction analyses have displayed that lopinavir and favipiravir analogues interact with the active site residues of Mpro and RdRp, respectively.	Lopinavir	51-60	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	138-142